以爱通立为对照,采用随机、多中心、盲法对rhM-tPA治疗急性ST段抬高型心肌梗死Ⅱ期临床研究
[Translation] A randomized, multicenter, blinded phase II clinical study of rhM-tPA in the treatment of acute ST-segment elevation myocardial infarction with Ai Tongli as the control
本研究是在Ⅱ期剂量探索试验基础上,权衡通栓有效性与安全性的平衡,以阿替普酶(爱通立)作为对照药,通过扩大样本量进一步评价rhM-tPA一次性静脉推注对急性ST段抬高型心肌梗死患者安全性与有效性研究。
[Translation] This study was based on a phase II dose-finding trial, and weighed the balance between the effectiveness and safety of thrombolytics. Alteplase (Aitongli) was used as a control drug. The safety and effectiveness of a one-time intravenous injection of rhM-tPA in patients with acute ST-segment elevation myocardial infarction were further evaluated by expanding the sample size.
100 Clinical Results associated with Beijing Shimao Dongrui Pharmaceutical Technology Co., Ltd.
0 Patents (Medical) associated with Beijing Shimao Dongrui Pharmaceutical Technology Co., Ltd.
100 Deals associated with Beijing Shimao Dongrui Pharmaceutical Technology Co., Ltd.
100 Translational Medicine associated with Beijing Shimao Dongrui Pharmaceutical Technology Co., Ltd.